Invasive fungal infections in ALL: a new ‘growth’ area

References

• Nicolato A, Nouér SA, Garnica M, et al. Invasive fungal diseases in patients with acute lymphoid leukemia. Leuk Lymphoma. 2016;57:2084–2089. DOI: 10.3109/10428194.2016.1154957.
   Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068–1075.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah M, Grigg A, Downey M, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97:459–463.
   PubMed Web of Science ®Google Scholar
• Doan TN, Kirkpatrick CM, Walker P, et al. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. J Antimicrob Chemother. 2016;71:497–505.
   PubMed Web of Science ®Google Scholar
• Henden A, Morris K, Truloff N, et al. Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis. Leuk Lymphoma. 2013;54:1329–1331.
   PubMed Web of Science ®Google Scholar
• Teng JC, Slavin MA, Teh BW, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100:e462–e466.
   PubMed Web of Science ®Google Scholar
• Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011;8:417–424.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408–1411.
   PubMed Web of Science ®Google Scholar
• Nucci M, Nouer SA, Cappone D, et al. Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica. 2013;98:1657–1660.
   PubMed Web of Science ®Google Scholar
• Even C, Bastuji-Garin S, Hicheri Y, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica. 2011;96:337–341.
   PubMed Web of Science ®Google Scholar
• Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55:290–297.
   PubMed Web of Science ®Google Scholar
• Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphblastic leukemia patients. J Oncol Pharm Pract. 2009;15:175–182.
   PubMedGoogle Scholar
• Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol. 2006;17:1306–1312.
   PubMed Web of Science ®Google Scholar
• Cornely O, Leguay T, Maertens J, et al. A double-blind, multicentre, randomised, placebo-controlled study to assess the efficacy, safety and tolerability of prophylactic liposomal amphotericin B (AmBisome®) for the prevention of invasive fungal infections in subjects receiving remission-induction chemotherapy for acute lymphoblastic leukaemia (AmBiGuard trial). Blood (Suppl). 2014;124:Abstract 3646.
   Google Scholar
• Fleming S, Yannakou CK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44:1283–1297.
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–1416.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Monte S, Algarotti A, et al. A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy. J Antimicrob Chemother. 2011;66:2140–2145.
   PubMed Web of Science ®Google Scholar
• Gomes MZ, Mulanovich VE, Jiang Y, et al. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid luekmeia patietnrs in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother. 2014;58:865–873.
   PubMed Web of Science ®Google Scholar
• Aguado JM, Vasquez L, Fernandez-Ruiz M, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy for invasive Aspergillosis in high-risk haematological patients: a randomized controlled trial. Clin Infect Dis. 2015;60:405–414.
   PubMed Web of Science ®Google Scholar
• Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13:519–528.
   PubMed Web of Science ®Google Scholar
• Hal SJ, Gilroy NM, Morrissey CO, et al. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand. Int Med J. 2014;44:1277–1282.
   Google Scholar
• Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006;24:5742–5749.
   PubMed Web of Science ®Google Scholar